X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs GLENMARK PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA GLENMARK PHARMA GSK PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 60.9 26.1 233.7% View Chart
P/BV x 11.4 3.6 320.6% View Chart
Dividend Yield % 2.5 0.3 855.4%  

Financials

 GSK PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
GLENMARK PHARMA
Mar-18
GSK PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,760930 296.8%   
Low Rs2,040517 394.3%   
Sales per share (Unadj.) Rs339.0322.6 105.1%  
Earnings per share (Unadj.) Rs41.428.5 145.4%  
Cash flow per share (Unadj.) Rs45.939.2 117.1%  
Dividends per share (Unadj.) Rs35.002.00 1,750.0%  
Dividend yield (eoy) %1.50.3 527.7%  
Book value per share (Unadj.) Rs242.9183.0 132.7%  
Shares outstanding (eoy) m84.70282.17 30.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.12.2 315.6%   
Avg P/E ratio x57.925.4 228.1%  
P/CF ratio (eoy) x52.318.5 283.1%  
Price / Book Value ratio x9.94.0 249.8%  
Dividend payout %84.57.0 1,203.8%   
Avg Mkt Cap Rs m203,280204,206 99.5%   
No. of employees `000NA13.7 0.0%   
Total wages/salary Rs m5,23418,718 28.0%   
Avg. sales/employee Rs ThNM6,636.8-  
Avg. wages/employee Rs ThNM1,364.7-  
Avg. net profit/employee Rs ThNM586.1-  
INCOME DATA
Net Sales Rs m28,71591,031 31.5%  
Other income Rs m545914 59.7%   
Total revenues Rs m29,26091,945 31.8%   
Gross profit Rs m5,05916,154 31.3%  
Depreciation Rs m3803,019 12.6%   
Interest Rs m22,856 0.1%   
Profit before tax Rs m5,22211,193 46.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,8923,155 60.0%   
Profit after tax Rs m3,5088,039 43.6%  
Gross profit margin %17.617.7 99.3%  
Effective tax rate %36.228.2 128.6%   
Net profit margin %12.28.8 138.3%  
BALANCE SHEET DATA
Current assets Rs m21,81569,887 31.2%   
Current liabilities Rs m15,99932,879 48.7%   
Net working cap to sales %20.340.7 49.8%  
Current ratio x1.42.1 64.1%  
Inventory Days Days6481 78.1%  
Debtors Days Days1993 20.0%  
Net fixed assets Rs m12,47528,892 43.2%   
Share capital Rs m847282 300.1%   
"Free" reserves Rs m19,72651,353 38.4%   
Net worth Rs m20,57351,635 39.8%   
Long term debt Rs m641,418 0.0%   
Total assets Rs m39,475125,954 31.3%  
Interest coverage x2,612.04.9 53,093.4%   
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x0.70.7 100.6%   
Return on assets %8.98.6 102.8%  
Return on equity %17.115.6 109.5%  
Return on capital %26.215.1 173.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56436,317 1.6%   
Fx outflow Rs m7,4299,720 76.4%   
Net fx Rs m-6,86526,598 -25.8%   
CASH FLOW
From Operations Rs m4,72816,481 28.7%  
From Investments Rs m-1,042-10,133 10.3%  
From Financial Activity Rs m-3,066-4,685 65.5%  
Net Cashflow Rs m6201,770 35.0%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 6.9 147.8%  
FIIs % 23.8 34.4 69.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 10.5 146.7%  
Shareholders   102,036 56,727 179.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  ELDER PHARMA  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 331 Points Higher; Oil & Gas Stocks Witness Buying(Closing)

After opening on a negative note, share markets in India witnessed buying interest during closing hours and ended the day on a positive note.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 13, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS